glp-1 pill form Health Canada approves first for high-risk type 2 diabetes patients GLP-1 Pills for Weight Loss:

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

While weight loss effects can vary depending on the drug, studies show that all GLP-1 meds can result in an average weight loss of about 10.5 to 15.8 []

Heart failure patients could be the next group to benefit from GLP-1 agonists, which are currently approved for the treatment of diabetes and obesity.

This review focuses on how GLP-1RAs impact lipid-related outcomes

Consume Protein-Rich Foods Protein promotes GLP-1 secretion, aiding satiety and blood sugar control

Promising Results: Early trials showed promising weight loss results, with parti